UPDATE: Pro-Pointer, Inc. Introduces a Revolutionary Approach to Weight Management
13 February 2010 - 12:04PM
Marketwired
Pro Pointer, Inc. (PINKSHEETS: PPII), through its wholly owned
subsidiary Coenzyme-A Technologies, Inc., is pleased to announce
its latest innovative proprietary formulation, the COENZYME A
MODULATOR MATRIX II™. The formula contains a balanced combination
of active nutritional components that support the body's natural
management of fat. This "BODY IMAGE™ product, in conjunction with
proper diet and exercise, can produce phenomenal results in fat
loss, while maintaining energy levels and preventing hunger and
weakness," stated Nickolaos D. Skouras, PhD, President/CEO
Coenzyme-A Technologies, Inc. "We are confident this is the first
nutraceutical product to combine nutritional components that can be
used by the body to support its manufacture and utilization of
Acetyl Coenzyme-A with a specific set of substrates that are
designed to assist the body in stabilizing blood sugar levels and
metabolizing fat," Dr. Skouras added.
The world nutraceutical market, which is expected to top $15
billion this year, has enjoyed double-digit growth over the last
few years and is expected to continue. Growth is believed to be
driven by new product introductions and health consciousness within
the aging populations. The US baby boomers, which are expected to
reach 80 million by 2012, drive the US market in the sense that
they are the generation which is most likely to demand control over
the course of their medical care. Coenzyme-A Technologies, Inc.
plans to penetrate this market through new and existing
distribution channels as well as the implementation of an
aggressive world-wide Internet marketing campaign.
ABOUT COENZYME-A TECHNOLOGIES, INC. -- Coenzyme-A Technologies,
Inc. is an innovative company that has applied new technology to
the formulation and manufacture of a series of proprietary products
which address nutritional deficiencies that result from the stress
of modern day living, chemical imbalances within the body, and the
deleterious effects of aging. Coenzyme-A is the first nutraceutical
product to combine nutritional components that can be successfully
used by the body to support its manufacture and utilization of
cellular Coenzyme-A (The Master Coenzyme). Coenzyme-A contains a
specific set of substrates that are designed to assist the body in
converting fats, carbohydrates and proteins into energy at the
cellular level. See Company website -- www.coenzyme-a.com.
FORWARD LOOKING STATEMENTS
The information contained in this news release, other than
historical information, consists of forward-looking statements
within the meaning of Section 27A of the Securities Act and Section
21E of the Exchange Act. These statements may involve risks and
uncertainties that could cause actual results to differ materially
from those described in such statements. Such forward-looking
statements involve known and unknown risks and uncertainties,
including all business uncertainties relating to product
development, marketing, market acceptance, future capital
requirements, competition in general and other factors that may
cause actual results to be materially different from those
described herein as anticipated, believed, estimated or expected.
The Company is under no obligation to (and expressly disclaims any
such obligation to) update or alter its forward-looking statements
whether as a result of new information, future events or
otherwise.
Add to Digg Bookmark with del.icio.us Add to Newsvine
INVESTOR RELATIONS at: InvestSource, Inc. 6352 Santa Ynez Dr.
Huntington Beach, CA 92647 Phone (714) 847-2460 Fax (714)
847-4987
Coenzyme A (CE) (USOTC:PPII)
Historical Stock Chart
From Nov 2024 to Dec 2024
Coenzyme A (CE) (USOTC:PPII)
Historical Stock Chart
From Dec 2023 to Dec 2024